LENSAR Q1 revenue $10.6M (+28% YoY); net loss narrows to $2.2M

LENSAR, Inc.

2024-Q1 EPS reported -$0.19 revenue$10,588,000

Total revenue $10.6M for Q1 2024, up 28% YoY; net loss $2.2M ($0.19 per share) vs $4.3M ($0.40) loss in Q1 2023.
Worldwide procedure volume increased 25% to 39,486; U.S. procedure volume up 23%. Installed base of ALLY systems reached 65.
U.S. procedure share grew 1.5% sequentially from Q4 2023, the highest single-quarter gain since ALLY launch; total share up 4.3% since launch.
Adjusted EBITDA loss improved to $1.3M from $1.8M; SG&A flat at $6.8M, R&D down 12% to $1.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LENSAR, Inc. reported quarter ended March 31, 2024 results: revenue $10.6 million, net income $2.2 million, EPS ($0.19) per common share.

Period: quarter ended March 31, 2024
Revenue: $10.6 million
Net income: $2.2 million
EPS: ($0.19) per common share
Result: reported results

Exact text from the filing

and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quarter of 2024. Total revenue for the quarter was $10.6 million, up 28% over the first quarter of 2023. Moreover, procedure volume grew by 23% in the U.S., our largest market and the only country where ALLY is currently marketed,” said Nick

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

LENSAR, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.